Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Placebo-controlled Proof oF Concept Clinical Study to Evaluate the Safety, Pharmacokinetics, AND Pharmacodynamics of Vaginal AZU-101 (Lasofoxifene Tartrate) in Postmenopausal Women

NCT06197568 is registered in ClinicalTrials.gov with Azure Biotech Inc. as lead sponsor.

NCT NCT06197568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06197568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Placebo-controlled Proof oF Concept Clinical Study to Evaluate the Safety, Pharmacokinetics, AND Pharmacodynamics of Vaginal AZU-101 (Lasofoxifene Tartrate) in Postmenopausal Women
Lead sponsor
Azure Biotech Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
June 1, 2026
Completion date
June 30, 2027
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

vulvo vaginal atrophy (vva)